There are currently no approved vaccines against the opportunistic pathogen Pseudomonas
aeruginosa. Among vaccine targets, the lipopolysaccharide (LPS) O antigen of P …

Background Nasopharyngeal swabs are taken to determine the causative agent of
community acquired pneumonia (CAP), while the reliability of upper respiratory tract …

Human infections caused by the opportunist pathogens Burkholderia cepacia complex and
Pseudomonas aeruginosa are of particular concern due to their severity, their multiple …

Background: Pseudomonas aeruginosa (PA) is a Gram-negative pathogen responsible for
fatal nosocomial infections worldwide. Iron is essential for Gram-negative bacteria to …

Despite numerous efforts to develop an effective vaccine against P seudomonas
aeruginosa, no vaccine has yet been approved for human use. This study investigates the …

Purpose The expression of MUC5AC, a highly prevalent airway mucin, is regulated by
stimulatory factors such as oxidative stress. Ganoderic acid D (GAD) activates mitochondrial …

Pseudomonas aeruginosa bacteria are becoming increasingly resistant against multiple
antibiotics. Therefore, the development of vaccines to prevent infections with these bacteria …

Pseudomonas is a group of bacteria that can cause a wide range of infections, particularly in
people with weakened immune systems, such as those with cystic fibrosis or who are …

Pseudomonas aeruginosa is an opportunistic human pathogen that is intrinsically resistant
to multiple antibiotics, causing severe and persistent infections in immunocompromised …

The recent outbreak of COVID-19 has increased hospital admissions, which could elevate
the risk of nosocomial infections, such as A. baumannii and P. aeruginosa infections …